Show simple item record

dc.contributor.authorPiccart, MJ
dc.contributor.authorHilbers, FS
dc.contributor.authorBliss, JM
dc.contributor.authorCaballero, C
dc.contributor.authorFrank, ES
dc.contributor.authorRenault, P
dc.contributor.authorNaït Kaoudjt, R
dc.contributor.authorSchumacher, E
dc.contributor.authorSpears, PA
dc.contributor.authorRegan, MM
dc.contributor.authorGelber, RD
dc.contributor.authorDavidson, NE
dc.contributor.authorNorton, L
dc.contributor.authorWiner, EP
dc.contributor.authorBIG-NABCG Collaboration
dc.date.accessioned2020-09-30T09:28:42Z
dc.date.issued2020-12
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 38 (34), pp. 4120 - 4129
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4082
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.20.01382
dc.description.abstractAn important challenge in the field of cancer is finding the balance between delivering effective treatments and avoiding adverse effects and financial toxicity caused by innovative, yet expensive, drugs. To address this, several treatment de-escalation trials have been conducted, but only a few of these have provided clear answers. A few trials had poor accrual or had design flaws that led to conflicting results. Members of the Breast International Group (BIG) and North American Breast Cancer Group (NABCG) believe the way forward is to understand the lessons from these trials and listen more carefully to what truly matters to our patients. We reviewed several adjuvant trials of different cancer types and developed a road map for improving the design and implementation of future de-escalation trials. The road map incorporates patients' insights obtained through focused group discussions across the BIG-NABCG networks. Considerations for the development of de-escalation trials for systemic adjuvant treatment, including noninferiority trial design, choice of end points, and prioritization of a patient's perspectives, are presented in this consensus article.
dc.formatPrint-Electronic
dc.format.extent4120 - 4129
dc.languageeng
dc.language.isoeng
dc.subjectBIG-NABCG Collaboration
dc.titleRoad Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
dc.typeJournal Article
dcterms.dateAccepted2020-08-18
rioxxterms.versionofrecord10.1200/jco.20.01382
rioxxterms.licenseref.startdate2020-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue34
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished
pubs.volume38en_US
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Uniten_US
dc.contributor.icrauthorBliss, Judithen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record